Amendments to and listing of the Claims:

Please amend the claims as follows. This listing of claims will replace all prior versions, and listings of claims in the application:

- 1. (Original) A composition for nasal delivery comprising zolpidem or a pharmaceutically acceptable salt thereof.
- 2. (Currently Amended) A<u>The</u> composition according to claim 1 in the form of a solution or a powder.
- 3. (Currently Amended) $\underline{A}\underline{\text{The}}$ composition according to claim 2 in the form of an aqueous solution.
- 4. (Currently Amended) A<u>The</u> composition according to any one of the preceding elaimsclaim 1, comprising a salt of zolpidem selected from the hydrochloride, mesilate, citrate, nitrate, lactate, maleate, tartrate, phosphate, succinate, fumarate and gluconate salts.
- 5. (Currently Amended) A<u>The</u> composition according to claim 4, wherein the salt is the tartrate salt.
- 6. (Currently Amended) A<u>The</u> composition according to any one of the preceding claims, claim 1, which is in the form of a solution and comprising from 0.8 to 97 mg/ml of zolpidem (expressed as the free base).
- 7. (Currently Amended) A<u>The</u> composition according to claim 6, comprising from 24 to 80 mg/ml of zolpidem (expressed as the free base).
- 8. (Currently Amended) A<u>The</u> composition according to claim 6, comprising from 2.4 to 16 mg/ml of zolpidem (expressed as the free base).
- 9. (Currently Amended) A<u>The</u> composition according to any one of the preceding elaimsclaim 1, in the form of a solution and comprising a solubility enhancing agent.
- 10. (Currently Amended) A<u>The</u> composition according to claim 9, wherein the solubility enhancing agent is a cyclodextrin.
- 11. (Currently Amended) A<u>The</u> composition according to claim 10, wherein the cyclodextrin is sulfobutylether-β-cyclodextrin (SBE-CD).

- 12. (Currently Amended) A<u>The</u> composition according to claim 11, comprising 50 to 700 mg/ml SBE-CD.
- 13. (Currently Amended) A<u>The</u> composition according to any one of the preceding elaims claim 1, having a pH of from 3.0 to 8.0.
- 14. (Currently Amended) A<u>The</u> composition according to any one of the preceding elaimsclaim 1, additionally comprising chitosan, a salt, a derivative thereof or a salt of a derivative thereof.
- 15. (Currently Amended) A<u>The</u> composition according to claim 14, comprising from 0.5 to 50 mg/ml of chitosan, a salt, a derivative thereof or a salt of a derivative thereof.
- 16. (Currently Amended) A<u>The</u> composition according to claim 1, which is an aqueous solution and comprises from 30 to 60 mg/ml of zolpidem tartrate, 100 to 300 mg/ml SBE-CD and 2 to 10 mg/ml of chitosan glutamate.
- 17. (Currently Amended) A<u>The</u> composition according to claim 1, which is an aqueous solution and comprises from 3 to 20 mg/ml of zolpidem tartrate and 2 to 10 mg/ml of chitosan glutamate.
- 18. (Currently Amended) A<u>The</u> composition according to any one of claims 1, 2 and 4 to 15, claim 1, in the form of a non-aqueous solution.
- 19. (Currently Amended) A<u>The</u> composition according to claim 18, comprising at least one of ethanol, propylene glycol, polyethylene glycol, glycofurol, benzyl benzoate and a polyoxyethylene castor oil derivative.
- 20. (Currently Amended) A<u>The</u> composition according to any one of claims 1, 2, 4 and 5claim 1, in the form of a powder.
- 21. (Currently Amended) A<u>The</u> composition according to claim 20, wherein the powder contains granules or microspheres.
- 22. (Currently Amended) A<u>The</u> composition according to claim 20 or 21,20, comprising 20 to 70 % by weight of zolpidem (expressed as free base).

- 23. (Currently Amended) A<u>The</u> composition according to any one of claims 20 to 22, claim 20, further comprising a means for improving the rate of dissolution of zolpidem in the nasal cavity.
- 24. (Currently Amended) A<u>The</u> composition according to claim 23, wherein the means is a cyclodextrin.
- 25. (Currently Amended) A<u>The</u> composition according to claim 24, wherein the ratio by weight of zolpidem or a pharmaceutically acceptable thereof to cyclodextrin is from 1:0.25 to 1:10.
- 26. (Currently Amended) A<u>The</u> composition according to claim <u>24 or 25,24</u>, wherein the cyclodextrin is sulfobutylether- β -cyclodextrin (SBE-CD).
- 27. (Currently Amended) A<u>The</u> composition according to any one of claims 20 to 26, claim 20, further comprising chitosan, a salt, a derivative thereof or a salt of a derivative thereof.
- 28. (Currently Amended) A<u>The</u> composition according to claim 27, comprising from 5 to 50 % by weight of chitosan, a salt, a derivative thereof or a salt of a derivative thereof.
- 29. (Original) The use of zolpidem or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for nasal administration to a patient in need thereof.
- 30. (Currently Amended) <u>Use The use</u> according to claim 29 in the manufacture of a medicament for the treatment or prevention of insomnia or for the treatment of a neurological disorder or for the treatment of Parkinson's disease.
- 31. (Currently Amended) Use The use according to claim 30, wherein the neurological disorder is one arising from brain trauma, stroke or spinocerebellar ataxia.
- 32. (Currently Amended) A method of administering zolpidem or a pharmaceutically acceptable salt thereof to a patient in need thereof, which method comprise the intranasal administration of a composition as defined in any one of claims 1 to 28. claim 1.
- 33. (Currently Amended) A method of treating or preventing insomnia, which method comprises the intranasal administration of a composition as defined in any one of claims 1 to 28.claim 1.

- 34. (Currently Amended) A method of treating a neurological disorder or Parkinson's disease, which method comprises the intranasal administration of a composition as defined in any one of claims 1 to 28.claim 1.
- 35. (Currently Amended) A method according to claim 34, wherein the neurological disorder is one arising from brain trauma, stroke or spinocerebellar ataxia.
- 36. (Currently Amended) A nasal drug delivery device or a dose cartridge for use in a nasal drug delivery device comprising a composition as defined in any one of claims 1 to 28.claim 1.